Drugs / AND017
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04712500 | Jul → Aug 2020 | — | Kind Pharmaceuticals LLC | Completed | No outcome recorded |
| Phase 1 | NCT04751539 | Jul 2018 → Feb 2019 | — | Kind Pharmaceuticals LLC | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT06075043 | Dec 2027 → May 2028 expected | aregenerative anemia | Kind Pharmaceuticals LLC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06075030 | Dec 2027 expected | chemotherapy-induced toxicity | Kind Pharmaceuticals LLC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06304103 | Mar 2025 → Dec 2026 expected | myelodysplastic syndrome | Kind Pharmaceuticals LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06302491 | May 2024 → Dec 2026 expected | beta thalassemia | Kind Pharmaceuticals LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT05265325 | May 2023 → Feb 2024 | anemia | Kind Pharmaceuticals LLC | Completed | No outcome recorded |
| Phase 2 | NCT05035641 | Oct 2021 → Jul 2023 | anemia | Kind Pharmaceuticals LLC | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07487727 | Dec 2025 → Dec 2026 expected | anemia due to chronic disorder | Kind Pharmaceuticals LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT07494409 | Oct 2025 → Oct 2026 expected | anemia due to chronic disorder | Kind Pharmaceuticals LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AND017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06075043 ↗ |
| Route | Oral | “following oral single-dose administration” NCT04712500 ↗ |